Armenia, Colombia

Fundacion Cardiomet Cequin

COVID-19

Venous Thromboembolism

Fibrosis

Idiopathic Pulmonary Fibrosis

Pulmonary Fibrosis

Thromboembolism

Hypertension

PF-07321332

Ritonavir

Pirfenidone

Deupirfenidone

Valsartan

Chlorthalidone

Pfizer

Boehringer Ingelheim

Farma de Colombia

Janssen (J&J Innovative Medicine)

PureTech Health

condition

allSponsorName

gender

Male

Female

overallStatus

Recruiting

Not yet recruiting

Active, not recruiting

Enrolling by invitation

Completed

Terminated

Withdrawn

Suspended

Unknown

type

Interventional

Observational

Expanded Access

phase

Early Phase 1

Phase 1

Phase 2

Phase 3

Phase 4

Not Applicable

funderTypes

Industry

Other U.S. Federal agency

All others

ageGroup

Child (birth-17)

Adult (18-64)

Older Adult (65+)

This study a randomized, double-blind, four arm study to evaluate the safety and efficacy of LYT-100 compared to pirfenidone or placebo in adults with Idiopathic Pulmonary Fibrosis.

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Fundacion Cardiomet Cequin | Armenia, Colombia

Site insights

Work at this site?

Active trials

LYT-100 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (ELEVATE)

Trial sponsors